SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Mix and Match Covid-19 Vaccine Study to Take Place in Mozambique

01/11/2022 | 05:06am EDT

Mozambique's National Health Institute (INS) will carry out research to investigate the effectiveness of mixing two approved Covid-19 vaccines.

A statement from the International Vaccine Institute (IVI) on 20 December announced that the INS-led Phase II trial will look at the safety and immunogenicity of a two-dose regimen using one dose of Sinopharm's VeroCell Covid-19 vaccine and one dose of the Johnson & Johnson vaccine administered 28 days apart. This will be compared with the effectiveness of the single source vaccines.

Both vaccines are approved and are part of Mozambique's COVID-19 vaccine rollout program.

There is evidence from around the world that mixing vaccines can produce a greater immune response. In addition, schedules where the second dose is not necessarily the same as the first allows for more flexibility in the event of vaccine shortages.

According to the deputy director of IVI, Doctor Florian Marks, "demonstrating the safety and efficacy of a mixed schedule of COVID-19 vaccines will have a significant impact on ensuring timely vaccinations and controlling the pandemic, particularly in the regions most affected by vaccine shortages".

She added, "amid an ongoing global pandemic with inequitable and interrupted access to vaccines, it is vital to make available a good, or potentially even better, alternative to the homologous dose schedules we have relied on so far".

The Phase II trial is an observer-blind and randomised study. A total of 360 participants will be enrolled in the study with follow-ups until 48 weeks after the second vaccination. It is funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and is part of a US$12.7 million project for Expanding Access and Delivery of COVID-19 Vaccines in Africa (ECOVA).

Since it was launched in 2017, CEPI has focussed on developing vaccines against the Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus and has over twenty vaccine candidates against these pathogens in development. The organisation is a partnership between public, private, philanthropic, and civil organisations.

IVI is a non-profit intergovernmental organisation established in 1997 through an initiative launched by the United Nations Development Programme (UNDP).

The INS is the national public health and research institute in Mozambique, an autonomous public entity that functions under the umbrella of the Ministry of Health. Its mission is to improve well-being through the generation of scientific and technological solutions for public health problems in Mozambique.

Copyright Agencia de Informacao de Mocambique. Distributed by AllAfrica Global Media (, source News Service English

All news about JOHNSON & JOHNSON
09:26aImmix Biopharma Says Cancer Drug IMX-110 Showed Higher Survival Rate Versus Johnson & J..
05/19The Janssen Pharmaceutical Companies - New Data Show TREMFYA (guselkumab) Binds to Both..
05/19New Janssen Campaign Developed by and for the LGBTQ+ Community Inspires Action and Empa..
05/18Thinking about trading options or stock in Costco, Dollar Tree, Micron, Upstart, or Joh..
05/17FDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11
05/17Citigroup Adjusts Price Target on Johnson & Johnson to $205 From $210, Reiterates Buy R..
05/16Mariners put RHP Steckenrider on restricted list, add Elías
05/13Idaho announces $119 million opioid crisis settlement
05/13What We're Reading This Week
05/12Johnson & Johnson to Participate in Goldman Sachs 43rd Annual Global Healthcare Confere..
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 96 248 M - -
Net income 2022 23 016 M - -
Net cash 2022 8 885 M - -
P/E ratio 2022 19,5x
Yield 2022 2,56%
Capitalization 458 B 458 B -
EV / Sales 2022 4,66x
EV / Sales 2023 4,43x
Nbr of Employees 141 700
Free-Float 84,2%
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 173,94 $
Average target price 186,82 $
Spread / Average Target 7,41%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON2.59%457 706
PFIZER, INC.-14.23%284 192
ABBVIE INC.12.05%268 106
ROCHE HOLDING AG-16.41%265 188
NOVO NORDISK A/S-0.56%236 239